Clinical Trials on Short Bowel Syndrome (SBS) in Japan

Total 23 results

Takeda

Recruiting

A Study of Teduglutide in Japanese People With Short Bowel Syndrome

Short Bowel Syndrome

Japan
Takeda
Takeda

Completed

An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004

Short Bowel Syndrome

Japan
Shire

Completed

Study of Teduglutide in Japanese Participants With Short Bowel Syndrome

Short Bowel Syndrome

Japan
Takeda

Completed

A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older

Short Bowel Syndrome

Japan
Shire

Completed

Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome (SBS)

Short Bowel Syndrome

Japan
Shire

Completed

Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral Support

Short Bowel Syndrome

Japan
Shire
Takeda

Completed

A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302

Short Bowel Syndrome

Japan
Astellas Pharma Inc

Completed

A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome

Constipation-predominant Irritable Bowel Syndrome (IBS-C)

Japan
VectivBio AG

Active, not recruiting

Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. (STARS extend)

Short Bowel Syndrome

United States, Belgium, United Kingdom, Korea, Republic of, Japan, Taiwan, Germany, France, Czechia, Hungary, Spain, Italy, Poland, Argentina, Denmark, Israel, Norway, Sweden
Astellas Pharma Inc

Completed

Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome With Constipation (IBS-C)

Japan
VectivBio AG

Completed

Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF (STARS)

Short Bowel Syndrome

United States, France, United Kingdom, Israel, Korea, Republic of, Germany, Japan, Taiwan, Sweden, Belgium, Spain, Czechia, Hungary, Norway, Italy, Argentina, Denmark, Poland
Astellas Pharma Inc

Completed

A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)

Diarrhea-predominant Irritable Bowel Syndrome

Japan
Astellas Pharma Inc

Completed

A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome

Diarrhea-predominant Irritable Bowel Syndrome

Japan
Astellas Pharma Inc

Completed

Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)

Irritable Bowel Syndrome With Constipation (IBS-C) | Chronic Constipation (CC) (Excluding Constipation Due to Organic Diseases)

Japan
Tohoku University

Unknown

Effect of Bifidobacterium on Irritable Bowel Syndrome (PBIBS)

Irritable Bowel Syndrome

Japan
Astellas Pharma Inc

Completed

A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients

Irritable Bowel Syndrome

Japan
Astellas Pharma Inc

Completed

A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome

Japan
Astellas Pharma Inc

Completed

A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female Patients

Irritable Bowel Syndrome

Japan
Astellas Pharma Inc

Completed

Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)

Irritable Bowel Syndrome

Japan
Astellas Pharma Inc

Completed

Special Drug Use Surveillance of Irribow in Female Patients

Diarrhea-predominant Irritable Bowel Syndrome

Japan
Novo Nordisk A/S

Completed

Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome)

Noonan Syndrome | Genetic Disorder

Japan
Novo Nordisk A/S

Completed

Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome

Noonan Syndrome | Genetic Disorder

Japan
Chugai Pharmaceutical

Not yet recruiting

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Antiphospholipid Syndrome (APS) | Immune Thrombocytopenia (ITP) | Dermatomyositis (DM) | Bullous Pemphigoid (BP) | Behçet's Syndrome (BS) | Immune-mediated Necrotizing Myopathy (IMNM)

United States, Japan

3

Subscribe